Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | SMC2 | O95347 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.43 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326016 | 0.90 | MAP2K1 (0.55) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4321805 | 0.89 | MAP2K1 (0.56) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4338451 | 0.83 | MAP2K1 (0.72) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL2880277 | 0.80 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29552961 | 0.80 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL29990156 | 0.80 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL4327409 | 0.79 | MAP2K1 (0.50) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL4321814 | 0.78 | MAP2K1 (0.49) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL1343357 | 0.78 | MAP2K1 (0.48) | MAP2K1MAP2K2 | |
| SCHEMBL26158812 | 0.76 | MAP2K1 (0.70) | MAP2K1MAP2K2ABCB11NQO2SMC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1689406-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689406-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 77/4885MAP2K2 63/4885ABCB11 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.